Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results
Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) defied analyst predictions to release its full-year results, which were ahead of market expectations. Revenues of US$17m beat estimates by a substantial 80% margin. Unfortunately, Tarsus Pharmaceuticals also reported a statutory loss of US$4.62 per share, which at least was smaller than the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
塔蘇斯製藥公司(納斯達克股票代碼:TARS)無視分析師的預期,公佈了其全年業績,該業績超出了市場預期。1700萬美元的收入比預期高出80%。不幸的是,塔蘇斯製藥還報告了每股4.62美元的法定虧損,至少低於分析師的預期。根據結果,分析師更新了他們的盈利模式,很高興知道他們是否認爲公司的前景發生了巨大變化,或者業務是否照舊。我們認爲,讀者會發現分析師對明年最新(法定)業績後的預測很有趣。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240302/0-d4f16784dd53d45891a808f78b7b0290-0-28694e66c03930d10e5c7638d4a8ac43.png/big)
Taking into account the latest results, the current consensus from Tarsus Pharmaceuticals' five analysts is for revenues of US$96.6m in 2024. This would reflect a major 454% increase on its revenue over the past 12 months. Losses are expected to increase substantially, hitting US$4.55 per share. Before this latest report, the consensus had been expecting revenues of US$62.3m and US$5.04 per share in losses. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.
考慮到最新業績,塔蘇斯製藥的五位分析師目前的共識是,2024年的收入爲9,660萬美元。這將反映其收入在過去12個月中大幅增長454%。預計虧損將大幅增加,達到每股4.55美元。在這份最新報告之前,共識一直預計收入爲6,230萬美元,每股虧損5.04美元。我們可以看到,在本次更新中,市場情緒肯定發生了變化,分析師對今年的收入估計進行了大幅上調,同時降低了虧損預期。
The consensus price target rose 11% to US$49.38, with the analysts encouraged by the higher revenue and lower forecast losses for next year. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Tarsus Pharmaceuticals at US$65.00 per share, while the most bearish prices it at US$30.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.
共識目標股價上漲11%,至49.38美元,分析師受到明年收入增加和預期虧損減少的鼓舞。但是,這並不是我們可以從這些數據中得出的唯一結論,因爲一些投資者在評估分析師目標股價時也喜歡考慮估計值的差異。目前,最看漲的分析師對Tarsus Pharmicals的估值爲每股65.00美元,而最看跌的分析師估值爲30.00美元。注意到分析師目標股價的巨大差距了嗎?對我們來說,這意味着基礎業務存在相當廣泛的可能情景。
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Tarsus Pharmaceuticals' growth to accelerate, with the forecast 5x annualised growth to the end of 2024 ranking favourably alongside historical growth of 23% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 9.0% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Tarsus Pharmaceuticals to grow faster than the wider industry.
了解這些預測的更多背景信息的一種方法是研究它們與過去的業績相比如何,以及同一行業中其他公司的表現。分析師們肯定預計,塔蘇斯製藥的增長將加速,預計到2024年底的5倍年化增長將保持在有利地位,而過去五年的歷史年增長率爲23%。相比之下,同行業的其他公司預計年收入將增長9.0%。顯而易見,儘管增長前景比最近更光明,但分析師也預計,Tarsus Pharmicals的增長速度將超過整個行業。
The Bottom Line
底線
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.
要了解的最重要的一點是,分析師重申了明年的每股虧損預期。令人高興的是,他們還上調了收入預期,他們的預測表明,該業務的增長速度預計將快於整個行業。我們注意到目標股價已上調,這表明分析師認爲該業務的內在價值可能會隨着時間的推移而提高。
With that in mind, we wouldn't be too quick to come to a conclusion on Tarsus Pharmaceuticals. Long-term earnings power is much more important than next year's profits. We have forecasts for Tarsus Pharmaceuticals going out to 2026, and you can see them free on our platform here.
考慮到這一點,我們不會很快就Tarsus Pharmicals得出結論。長期盈利能力比明年的利潤重要得多。我們對Tarsus Pharmicals的預測將持續到2026年,你可以在我們的平台上免費查看。
You still need to take note of risks, for example - Tarsus Pharmaceuticals has 1 warning sign we think you should be aware of.
例如,您仍然需要注意風險——Tarsus Pharmaceuticals有1個警告信號,我們認爲您應該注意。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。